Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Moodys
Mallinckrodt
Merck
Harvard Business School

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,067,427

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,067,427 protect, and when does it expire?

Patent 8,067,427 protects CAPRELSA and is included in one NDA.

This patent has thirty-nine patent family members in thirty-two countries.

Summary for Patent: 8,067,427
Title:Pharmaceutical compositions comprising ZD6474
Abstract: A pharmaceutical composition comprising ZD6474 or a pharmaceutically acceptable salt thereof, a brittle diluent and a second diluent which is practically insoluble and has ductile compression properties.
Inventor(s): Stott; Paul William (Wilmington, DE)
Assignee: AstraZeneca AB (Sodertajle, SE)
Application Number:11/596,979
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,067,427

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No   Start Trial   Start Trial Y   Start Trial
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,067,427

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0411378.3May 21, 2004
PCT Information
PCT FiledMay 18, 2005PCT Application Number:PCT/GB2005/001931
PCT Publication Date:December 01, 2005PCT Publication Number: WO2005/112934

International Family Members for US Patent 8,067,427

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 049059   Start Trial
Argentina 110045   Start Trial
Austria 439841   Start Trial
Australia 2005244650   Start Trial
Brazil PI0511253   Start Trial
Canada 2565513   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Express Scripts
McKesson
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.